^
Association details:
| Biomarker: | NTRK1 mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report
Published date:
07/01/2022
Excerpt:
...tumor organoids have been generated from the resected HCC-NED and extensively characterized….With genomic analysis revealing a NTRK1-mutation of unknown significance (kinase domain) and tumor organoids found to be sensitive to entrectinib, a pan-TRK inhibitor...
DOI:
https://doi.org/10.1038/s43856-022-00150-3
